Aripiprazole STADA Arzneimittel AG
Long-Acting Injectable Atypical Antipsychotic – Depot Suspension for Schizophrenia Maintenance
Aripiprazole STADA Arzneimittel AG is a long-acting injectable (LAI) antipsychotic medication containing aripiprazole as its active substance, supplied as a powder and solvent for prolonged-release depot suspension at a strength of 300 mg. This formulation is manufactured by STADA Arzneimittel AG and is designed for once-monthly intramuscular injection to provide sustained maintenance treatment of schizophrenia in adult patients who have been stabilized on oral aripiprazole. As a generic alternative to branded aripiprazole depot products, it offers the same pharmacological benefits of aripiprazole’s unique partial dopamine agonist mechanism while improving medication adherence through less frequent dosing.
Quick Facts: Aripiprazole STADA
Key Takeaways
- Aripiprazole STADA is a long-acting injectable (depot) formulation of aripiprazole given once monthly by intramuscular injection, eliminating the need for daily oral medication and improving treatment adherence in schizophrenia.
- The 300 mg dose is supplied as a powder and solvent that must be reconstituted by a healthcare professional before injection into the gluteal or deltoid muscle.
- Patients must first be stabilized on oral aripiprazole before switching to the depot formulation, and oral supplementation is typically needed for approximately 14 days after the first injection.
- As a partial dopamine agonist, aripiprazole has a generally favorable metabolic profile with lower risk of weight gain, sedation, and prolactin elevation compared to many other antipsychotics.
- Important safety warnings include increased mortality in elderly patients with dementia-related psychosis, risk of impulse control disorders (pathological gambling, compulsive behaviors), neuroleptic malignant syndrome, and tardive dyskinesia.
What Is Aripiprazole STADA Arzneimittel AG and What Is It Used For?
Aripiprazole STADA Arzneimittel AG belongs to the class of medications known as atypical (second-generation) antipsychotics, sometimes referred to as third-generation due to its distinct pharmacological profile. The product is manufactured by STADA Arzneimittel AG, one of the leading generic pharmaceutical companies in Europe, and represents a generic alternative to branded long-acting aripiprazole depot products such as Abilify Maintena.
The active substance, aripiprazole, was originally developed by Otsuka Pharmaceutical and first approved by the United States Food and Drug Administration (FDA) in 2002 for oral use. The long-acting injectable formulation was subsequently developed to address one of the most significant challenges in schizophrenia treatment: medication non-adherence. Research consistently demonstrates that up to 50% of patients with schizophrenia do not take their oral medications as prescribed, which significantly increases the risk of relapse, hospitalization, and poor long-term outcomes. The depot formulation addresses this by providing therapeutic drug levels for approximately four weeks after a single intramuscular injection.
What distinguishes aripiprazole from virtually all other antipsychotic medications is its unique mechanism of action. While most antipsychotics work by blocking dopamine D2 receptors, aripiprazole functions as a partial agonist at these receptors. This means that in brain regions where dopamine activity is excessively high (the mesolimbic pathway, associated with positive psychotic symptoms such as hallucinations and delusions), aripiprazole reduces dopamine signaling. Conversely, in brain regions where dopamine activity is insufficient (the mesocortical pathway, associated with negative symptoms and cognitive deficits), it enhances dopamine signaling. This bidirectional action has earned aripiprazole the description of a dopamine system stabilizer.
In addition to its dopamine-modulating effects, aripiprazole acts as a partial agonist at serotonin 5-HT1A receptors and an antagonist at serotonin 5-HT2A receptors. This combined pharmacological profile contributes to its relatively favorable side effect profile, particularly regarding metabolic effects (weight gain, dyslipidemia, glucose dysregulation), sedation, and prolactin elevation, when compared to other atypical antipsychotics such as olanzapine, quetiapine, or risperidone.
The primary approved indication for Aripiprazole STADA depot injection is:
- Maintenance treatment of schizophrenia in adults: For patients aged 18 years and older who have been stabilized on oral aripiprazole and have demonstrated tolerability and a satisfactory clinical response. The depot formulation is not intended for the acute treatment of schizophrenia episodes; rather, it is used once the patient has achieved stability on oral medication and the clinician wishes to transition to a long-acting injectable for improved adherence and relapse prevention.
Clinical trials have demonstrated that aripiprazole long-acting injectable significantly reduces the risk of relapse compared to placebo in patients with schizophrenia. A pivotal randomized, double-blind study published in the Journal of Clinical Psychiatry showed that the aripiprazole depot formulation reduced the risk of impending relapse by approximately 5-fold compared to placebo over a 52-week period. Furthermore, the depot formulation provides more consistent plasma drug levels than oral administration, which may contribute to improved symptom control and reduced breakthrough episodes.
Long-acting injectable antipsychotics like Aripiprazole STADA offer several advantages over oral formulations: guaranteed medication delivery (eliminating concerns about non-adherence), consistent plasma drug levels without daily peaks and troughs, reduced risk of accidental or intentional overdose from oral medication, early detection of non-adherence (missed clinic appointments are immediately apparent), and improved long-term outcomes including fewer relapses and hospitalizations. The transition to depot treatment should be a shared decision between the patient and their healthcare team.
What Should You Know Before Taking Aripiprazole STADA?
Before initiating treatment with Aripiprazole STADA depot injection, several important prerequisites and precautions must be addressed. Unlike oral antipsychotic treatment that can be started directly, the depot formulation requires prior stabilization on oral aripiprazole to confirm that the patient tolerates the medication well and responds clinically.
Contraindications
You should not receive Aripiprazole STADA depot injection if you are allergic (hypersensitive) to aripiprazole or any of the other ingredients in this product. Signs of a severe allergic reaction may include skin rash, hives, itching, facial or throat swelling, and difficulty breathing. If you experience any of these symptoms following injection, seek emergency medical attention immediately. Because the depot formulation releases aripiprazole slowly over several weeks, allergic reactions may persist longer than with oral formulations and require extended monitoring.
Elderly patients with dementia-related psychosis treated with antipsychotic medications, including aripiprazole, are at an increased risk of death. Aripiprazole STADA is not approved for the treatment of patients with dementia-related psychosis. Additionally, cerebrovascular adverse events (stroke and transient ischemic attack) have been reported in elderly patients with dementia receiving aripiprazole. This warning applies to all formulations of aripiprazole.
Suicidal thoughts and behaviors have been reported during treatment with antipsychotics, including aripiprazole. Patients, families, and caregivers should be alert to any changes in mood, behavior, or suicidal ideation, particularly during the early months of treatment or after dose changes. Report any concerns to the treating physician immediately.
Warnings and Precautions
Before starting Aripiprazole STADA depot injection, tell your doctor if you have any of the following conditions, as they may require special monitoring or consideration:
- Diabetes or risk factors for diabetes: Aripiprazole can affect blood glucose levels. Although the metabolic risk with aripiprazole is lower than with some other antipsychotics, blood glucose monitoring is recommended, particularly in patients with established diabetes or those with risk factors such as obesity, family history of diabetes, or previous glucose intolerance.
- Cardiovascular disease: Including coronary artery disease, heart failure, conduction abnormalities, cerebrovascular disease, or conditions that predispose to hypotension (dehydration, hypovolemia, concurrent antihypertensive treatment). Aripiprazole can cause orthostatic hypotension, which may lead to dizziness, lightheadedness, or syncope (fainting), especially during the initial period of treatment.
- Seizure disorders or history of seizures: Aripiprazole may lower the seizure threshold. Patients with a history of seizures or conditions that lower seizure threshold should be monitored closely.
- History of blood clots: Venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE), has been reported with antipsychotic medications. Risk factors for VTE should be identified before and during treatment.
- Liver impairment: No dose adjustment is required for mild to moderate hepatic impairment. However, patients with severe liver disease should be monitored carefully as aripiprazole is extensively metabolized by the liver.
- Renal impairment: No dose adjustment is necessary for patients with kidney disease, as renal excretion of unchanged aripiprazole is minimal.
Aripiprazole has been associated with the development of impulse control disorders, including pathological gambling, compulsive eating, compulsive shopping, and hypersexuality. These behaviors may emerge or worsen during treatment and can be difficult for patients themselves to recognize. Patients and their caregivers should be made aware of this risk before starting treatment. If these behaviors develop, the prescribing physician should consider dose reduction or discontinuation. Because aripiprazole depot has a prolonged duration of action, impulse control disorders may persist for weeks after the last injection.
Pregnancy and Breastfeeding
If you are pregnant, planning to become pregnant, or breastfeeding, discuss this with your doctor before receiving Aripiprazole STADA depot injection. The use of antipsychotics during pregnancy requires careful evaluation of the benefits of treating the mother's psychiatric condition against potential risks to the developing fetus. Due to the long-acting nature of the depot formulation, aripiprazole will remain in the body for several weeks after the last injection, which is an important consideration for women of childbearing potential.
Neonates exposed to antipsychotic drugs during the third trimester of pregnancy may experience withdrawal symptoms or extrapyramidal symptoms after delivery. These can include tremor, muscle rigidity or floppiness, drowsiness, agitation, breathing difficulties, and feeding problems. These effects are typically self-limiting but may require neonatal monitoring and supportive care. Given the depot formulation’s prolonged release profile, discuss pregnancy planning with your doctor well in advance so that a safe transition plan can be developed.
Aripiprazole is excreted in human breast milk. The decision to breastfeed while receiving depot aripiprazole should be made in consultation with your physician, weighing the benefits of breastfeeding against the potential exposure of the infant to the medication. Because the depot formulation cannot be quickly discontinued (drug levels decline gradually over weeks), this decision should ideally be made before treatment begins.
Driving and Operating Machinery
Aripiprazole may cause dizziness, somnolence (sleepiness), and visual disturbances. Patients should not drive or operate machinery until they understand how the depot injection affects them personally. Because the depot formulation can cause sustained plasma levels, side effects that affect alertness may persist longer than with oral formulations.
How Does Aripiprazole STADA Interact with Other Drugs?
Drug interactions with Aripiprazole STADA depot injection are primarily related to the metabolism of aripiprazole through the cytochrome P450 enzyme system, particularly the CYP2D6 and CYP3A4 isoenzymes. Understanding these interactions is critical because, unlike oral formulations where dose adjustments take effect within days, changes to depot injection dosing require a longer period to reach new steady-state levels due to the prolonged-release characteristics of the formulation.
Major Interactions
The following interactions are clinically significant and typically require dose adjustments or avoidance:
| Interacting Drug / Class | Effect | Clinical Recommendation |
|---|---|---|
| Strong CYP2D6 inhibitors (fluoxetine, paroxetine, quinidine) | Significantly increase aripiprazole plasma levels by inhibiting primary metabolism | Reduce depot dose from 300 mg to 200 mg monthly |
| Strong CYP3A4 inhibitors (ketoconazole, itraconazole, clarithromycin) | Increase aripiprazole plasma levels by inhibiting secondary metabolism | Reduce depot dose from 300 mg to 200 mg monthly |
| Combined CYP2D6 + CYP3A4 inhibitors | Markedly increased aripiprazole exposure; risk of toxicity | Avoid combination or reduce dose significantly; close monitoring required |
| Strong CYP3A4 inducers (carbamazepine, rifampicin, phenytoin, St. John’s Wort) | Substantially decrease aripiprazole plasma levels, reducing efficacy | Avoid co-administration with depot formulation if possible; if necessary, supplement with oral aripiprazole |
| Antihypertensive medications | Enhanced blood pressure-lowering effect; increased risk of orthostatic hypotension | Monitor blood pressure closely, especially after injection; adjust doses as needed |
Other Notable Interactions
Several additional medication categories warrant awareness when used alongside aripiprazole depot injection:
- Benzodiazepines and CNS depressants: Combining aripiprazole with benzodiazepines, opioids, or other central nervous system depressants may cause increased sedation, respiratory depression, and dizziness. The long-acting nature of the depot injection means that sedative effects may persist for an extended period.
- Serotonergic drugs (SSRIs, SNRIs, triptans, tramadol): Co-administration may increase the risk of serotonin syndrome, a potentially life-threatening condition characterized by agitation, confusion, fever, sweating, and muscle rigidity. Monitor for these symptoms, particularly when initiating or increasing serotonergic medication alongside the depot injection.
- Antiarrhythmic drugs (amiodarone, flecainide): Some antiarrhythmics inhibit CYP2D6 and may increase aripiprazole levels. They may also prolong the QT interval, requiring cardiac monitoring when used alongside aripiprazole.
- Alcohol: Alcohol should be avoided while receiving aripiprazole depot injections. Although aripiprazole does not significantly potentiate the cognitive or motor effects of alcohol in clinical studies, alcohol can worsen the underlying psychiatric condition and increase the risk of side effects such as dizziness and sedation.
Approximately 5–10% of the Caucasian population are CYP2D6 poor metabolizers, meaning they break down aripiprazole much more slowly and naturally have higher drug levels. For CYP2D6 poor metabolizers receiving the depot injection, the recommended dose is 200 mg monthly instead of 300 mg. If a CYP2D6 poor metabolizer is also taking a strong CYP3A4 inhibitor, the depot formulation should be avoided or used with extreme caution under specialist supervision. Pharmacogenomic testing can identify these patients before treatment initiation.
What Is the Correct Dosage of Aripiprazole STADA?
The dosing of Aripiprazole STADA depot injection follows specific protocols designed to ensure a smooth transition from oral aripiprazole to the long-acting injectable formulation. All injections must be administered by a healthcare professional; this medication is not designed for self-administration.
Adults – Schizophrenia Maintenance
| Phase | Dose | Route | Duration / Frequency |
|---|---|---|---|
| Oral stabilization (prerequisite) | 10–20 mg/day oral aripiprazole | Oral | At least 2 weeks to confirm tolerability |
| First depot injection | 300 mg | Intramuscular (deltoid or gluteal) | Single injection + oral overlap for 14 days |
| Oral overlap period | 10–20 mg/day oral aripiprazole | Oral | 14 consecutive days after first injection |
| Maintenance | 300 mg (or 200 mg if dose reduction needed) | Intramuscular (deltoid or gluteal) | Once monthly (every 4 weeks) |
| CYP2D6 poor metabolizers or strong CYP inhibitor co-administration | 200 mg | Intramuscular (deltoid or gluteal) | Once monthly (every 4 weeks) |
The injection site should be alternated between the gluteal and deltoid muscles, and between left and right sides, to minimize the risk of injection site reactions. When injecting into the deltoid muscle, a 21-gauge needle is typically used, while gluteal injections may require a slightly longer needle depending on the patient’s body habitus. The reconstituted suspension should be injected slowly and steadily.
Children and Adolescents
Not recommended for patients under 18 years
The safety and efficacy of aripiprazole depot injection in children and adolescents under 18 years of age have not been established. This formulation should only be used in adult patients (18 years and older). For pediatric patients requiring aripiprazole, the oral tablet formulation is available with age-appropriate dosing guidelines under specialist supervision.
Elderly Patients
No routine dose adjustment is required for elderly patients with schizophrenia. However, elderly patients may be more susceptible to orthostatic hypotension, sedation, and falls. Lower initial caution and careful monitoring are advisable. As noted in the warnings section, aripiprazole depot injection is not approved for elderly patients with dementia-related psychosis due to increased risk of death and cerebrovascular events.
Missed Dose
If you miss a scheduled depot injection appointment, the guidance depends on how long it has been since the missed dose:
- Missed by less than 2 weeks: Receive the injection as soon as possible and resume the regular monthly schedule.
- Missed by 2–3 weeks: Receive the injection as soon as possible. No oral supplementation is typically needed.
- Missed by more than 4 weeks: Restart oral aripiprazole supplementation for 14 days alongside the next depot injection, similar to the initial transition protocol. Your doctor will determine the appropriate approach based on your clinical situation.
Contact your healthcare provider as soon as possible if you realize you have missed an appointment. Consistent monthly injections are important for maintaining stable symptom control and preventing relapse.
Overdose
Overdose with the depot formulation is unlikely under normal circumstances as the injection is administered by a healthcare professional. However, if an excessive dose is inadvertently administered, the patient should be monitored closely in a medical facility. Because the depot formulation releases aripiprazole slowly over weeks, symptoms of overdose may be prolonged and require extended monitoring. Symptoms may include drowsiness, lethargy, rapid heartbeat, low blood pressure, agitation, seizures, extrapyramidal symptoms, and altered consciousness.
There is no specific antidote for aripiprazole overdose. Treatment is supportive, with close monitoring of vital signs, cardiac function (ECG), and airway management as needed. Due to the prolonged-release nature of the depot formulation, observation may need to continue for several days or longer. Contact your local emergency services or poison control center for guidance.
What Are the Side Effects of Aripiprazole STADA?
Like all medications, Aripiprazole STADA depot injection can cause side effects, although not everyone will experience them. The side effect profile is generally similar to oral aripiprazole, with the addition of injection site reactions which are specific to the depot formulation. Clinical trials of aripiprazole long-acting injectable have demonstrated that the medication is generally well-tolerated, with a safety profile consistent with the known effects of oral aripiprazole.
The following side effects are organized by frequency based on clinical trial data and post-marketing surveillance:
Very Common
May affect more than 1 in 10 people
- Injection site pain (reported in up to 33% of patients in clinical trials; usually mild and transient)
- Weight gain (particularly during the first few months of treatment)
Common
May affect up to 1 in 10 people
- Akathisia (inner restlessness, inability to sit still)
- Extrapyramidal symptoms (tremor, involuntary twitching or stiffness)
- Insomnia and sleep disturbances
- Anxiety and restlessness
- Headache
- Dizziness and lightheadedness
- Drowsiness and fatigue
- Nausea and vomiting
- Constipation
- Injection site induration (hardening at injection site)
- Injection site erythema (redness at injection site)
- Musculoskeletal stiffness
- Increased blood creatine phosphokinase
Uncommon
May affect up to 1 in 100 people
- Elevated or reduced prolactin levels
- High blood sugar (hyperglycemia)
- Depression
- Altered or increased sexual interest
- Tardive dyskinesia (uncontrollable movements of mouth, tongue, or limbs)
- Dystonia (sustained muscle contractions)
- Tachycardia (rapid heartbeat)
- Orthostatic hypotension (dizziness when standing)
- Dry mouth
- Injection site swelling or pruritus (itching)
- Diabetes mellitus
Rare or Frequency Not Known
Reported in post-marketing surveillance
- Neuroleptic malignant syndrome (NMS): fever, severe muscle rigidity, rapid breathing, sweating, altered consciousness, sudden changes in blood pressure and heart rate
- Serotonin syndrome: euphoria, drowsiness, restlessness, fever, sweating, rigid muscles
- Seizures (convulsions)
- Severe allergic reactions including anaphylaxis
- Venous thromboembolism (blood clots in legs or lungs)
- Rhabdomyolysis (abnormal muscle breakdown)
- Hepatitis and liver function abnormalities
- Pancreatitis
- Suicidal thoughts and suicide attempts
- Impulse control disorders: pathological gambling, compulsive eating, compulsive shopping, hypersexuality
- Life-threatening cardiac arrhythmias
- Aspiration pneumonia
- Difficulty swallowing (dysphagia)
- Hair loss (alopecia)
- Excessive sweating
Contact your doctor or emergency services immediately if you experience: high fever with severe muscle stiffness, sweating, and altered consciousness (signs of neuroleptic malignant syndrome); uncontrollable muscle movements especially of the face or tongue (signs of tardive dyskinesia); chest pain and difficulty breathing (possible blood clot); severe allergic reaction with swelling of face, lips, or throat; or thoughts of self-harm. Because the depot formulation cannot be removed once injected, medical monitoring may need to continue for an extended period.
Injection site reactions are the most notable difference in the side effect profile between the depot and oral formulations. In clinical trials, injection site pain was reported by approximately one-third of patients, but was generally rated as mild and typically resolved within a few days. Injection site induration (hardening) and erythema (redness) were less common. Rotating injection sites between gluteal and deltoid muscles, and alternating between sides, can help minimize these local reactions.
It is important to report any suspected side effects to your healthcare provider. Ongoing pharmacovigilance allows continuous monitoring of the benefit-risk balance of medications after they have been approved for clinical use.
How Should You Store Aripiprazole STADA?
Proper storage of Aripiprazole STADA is essential to maintain the medication’s effectiveness and safety. As a powder and solvent for suspension, specific storage and handling requirements must be followed:
- Unopened product: Store at room temperature below 30°C (86°F). Keep the powder vial and solvent in their original packaging to protect from light and moisture. Do not refrigerate or freeze, as this may affect the reconstitution properties of the powder.
- Reconstituted suspension: Once the powder has been reconstituted with the provided solvent, the suspension should be used promptly. The reconstituted product should not be stored for later use. Follow the manufacturer’s instructions regarding the maximum time between reconstitution and injection.
- Professional handling: The reconstitution and injection process should be performed by a trained healthcare professional in a clinical setting. The product requires vigorous shaking after reconstitution to ensure a uniform suspension before injection.
Always check the expiry date on the packaging before reconstitution. The expiry date refers to the last day of the stated month. Do not use the product if the powder appears discolored or if the packaging shows signs of damage. Return unused or expired medications to a pharmacy for proper disposal to protect the environment. Do not dispose of medications via household waste or drain.
What Does Aripiprazole STADA Contain?
Aripiprazole STADA Arzneimittel AG depot injection consists of two components that are combined (reconstituted) immediately before administration:
Powder Vial
The powder vial contains aripiprazole as the active substance at a dose of 300 mg. The powder is formulated as a lyophilized (freeze-dried) preparation designed to form a prolonged-release suspension when reconstituted with the provided solvent. Excipients in the powder may include carboxymethylcellulose sodium, mannitol, sodium dihydrogen phosphate monohydrate, and sodium hydroxide for pH adjustment. These excipients are necessary to create the depot matrix that enables the slow, sustained release of aripiprazole from the injection site over approximately four weeks.
Solvent Vial
The solvent provided for reconstitution is sterile water for injections. This is used to reconstitute the lyophilized powder into a homogeneous suspension suitable for intramuscular injection. The solvent may also contain trace amounts of stabilizers or buffering agents as specified in the product information.
Reconstituted Suspension
When the powder is reconstituted with the solvent and vigorously shaken, it forms a white to off-white, opaque, aqueous suspension. This suspension must be injected immediately after preparation. The suspension should appear homogeneous without visible clumps; if clumps persist after adequate shaking, the product should not be used. The entire content of the reconstituted vial constitutes a single dose and should be administered in a single injection.
Frequently Asked Questions About Aripiprazole STADA
Aripiprazole STADA depot injection works by forming a slow-release reservoir of aripiprazole at the injection site (either the gluteal or deltoid muscle). After intramuscular injection, the aripiprazole gradually dissolves from the depot into the surrounding tissue and is absorbed into the bloodstream over approximately four weeks. This provides consistent, sustained therapeutic drug levels that help maintain symptom control in schizophrenia without the need for daily oral medication. The active ingredient, aripiprazole, stabilizes dopamine signaling in the brain by acting as a partial agonist at dopamine D2 receptors, which helps control both positive symptoms (hallucinations, delusions) and negative symptoms (social withdrawal, apathy) of schizophrenia.
Aripiprazole STADA depot injection is administered once every month (every 4 weeks) by a healthcare professional. You will need to attend a clinic, outpatient department, or your psychiatrist’s office for each injection. The injection takes only a few minutes, but you may be asked to stay briefly for observation, particularly during the first few injections. Keeping to a regular monthly schedule is important for maintaining stable drug levels and consistent symptom control. If you need to reschedule an appointment, try to do so within a few days of the planned date to minimize fluctuations in drug levels.
Yes, this is the standard pathway to starting the depot injection. You must first be stabilized on oral aripiprazole for at least two weeks to confirm that you tolerate the medication and respond well clinically. When you receive your first depot injection, you will continue taking oral aripiprazole for an additional 14 days to maintain therapeutic drug levels while the depot formulation builds up in your system. After this 14-day overlap period, you can stop the oral tablets and rely solely on the monthly injection. Your psychiatrist will guide you through this transition and monitor your response closely during the changeover period.
Aripiprazole STADA Arzneimittel AG is a generic version of the long-acting aripiprazole depot injection. While Abilify Maintena is the original branded product developed by Otsuka and Lundbeck, the STADA generic contains the same active ingredient (aripiprazole) and is designed to deliver the same therapeutic effect. Generic medications in the European Union must meet stringent regulatory requirements to demonstrate bioequivalence with the reference product, meaning they deliver the same amount of active drug at the same rate. Your doctor may prescribe either the branded or generic version depending on availability, cost considerations, and local formulary guidelines.
If you miss your scheduled injection, contact your healthcare provider as soon as possible. Due to the long-acting nature of the depot formulation, missing an injection by a few days is unlikely to cause significant problems. If the injection is missed by less than two weeks, it can simply be given as soon as possible with the regular schedule resumed. If it is missed by more than four weeks, your doctor may recommend restarting oral aripiprazole supplementation for 14 days alongside the next injection, similar to the initial transition protocol. The most important thing is to communicate with your treatment team so they can adjust the plan accordingly.
Yes, aripiprazole, including the depot formulation, has been associated with impulse control disorders such as pathological gambling, compulsive eating, compulsive shopping, and hypersexuality. This risk is thought to be related to aripiprazole’s partial dopamine agonist mechanism, which may overstimulate reward pathways in susceptible individuals. The European Medicines Agency (EMA) has issued safety communications about this risk. An important consideration with the depot formulation is that these effects may persist for several weeks after the last injection because aripiprazole levels decline gradually. If you or your caregivers notice unusual urges or behaviors, report them to your doctor promptly so that dose reduction or treatment changes can be considered.
References
- European Medicines Agency (EMA). Aripiprazole STADA – Summary of Product Characteristics. Available at: www.ema.europa.eu
- European Medicines Agency (EMA). Abilify Maintena – EPAR Summary for the Public. Last updated 2025. Available at: www.ema.europa.eu/en/medicines/human/EPAR/abilify-maintena
- U.S. Food and Drug Administration (FDA). Abilify Maintena (aripiprazole) Extended-Release Injectable Suspension Prescribing Information. Available at: www.accessdata.fda.gov
- World Health Organization (WHO). Model List of Essential Medicines, 23rd List (2023). Geneva: WHO; 2023.
- Kane JM, Sanchez R, Perry PP, et al. Aripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia: a 52-week, multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2012;73(5):617-624. doi:10.4088/JCP.11m07530
- Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013;382(9896):951-962. doi:10.1016/S0140-6736(13)60733-3
- National Institute for Health and Care Excellence (NICE). Psychosis and schizophrenia in adults: prevention and management. Clinical guideline CG178. Updated 2024.
- De Hert M, Detraux J, van Winkel R, et al. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol. 2012;8(2):114-126. doi:10.1038/nrendo.2011.156
- European Medicines Agency (EMA). PRAC assessment report: Aripiprazole – Impulse control disorders. EMA/165578/2016. Available at: www.ema.europa.eu
- British National Formulary (BNF). Aripiprazole. NICE Evidence Services. Updated 2025. Available at: bnf.nice.org.uk/drugs/aripiprazole
- Correll CU, Citrome L, Haddad PM, et al. The use of long-acting injectable antipsychotics in schizophrenia: evaluating the evidence. J Clin Psychiatry. 2016;77(suppl 3):1-24. doi:10.4088/JCP.15032su1
Editorial Team
Medical Content
iMedic Medical Editorial Team – Specialists in Psychiatry and Clinical Pharmacology with documented academic background and clinical experience.
Medical Review
iMedic Medical Review Board – Independent panel of physicians who verify medical accuracy, evidence quality, and adherence to international guidelines (WHO, EMA, FDA, NICE, BNF).
Evidence Standard
Level 1A evidence based on systematic reviews, meta-analyses, and randomized controlled trials. GRADE evidence framework applied. No commercial funding.
Accessibility
Content reviewed for WCAG 2.2 Level AAA compliance. Optimized for screen readers, keyboard navigation, and assistive technology. High contrast support enabled.
Disclaimer: This article is for educational purposes only and does not replace professional medical advice. Always consult a qualified healthcare provider before starting, changing, or stopping any medication.